Farallon Capital Management LLC Boosts Stock Holdings in Beta Bionics, Inc. $BBNX

Farallon Capital Management LLC grew its stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) by 2.6% during the third quarter, Holdings Channel reports. The institutional investor owned 4,313,920 shares of the company’s stock after purchasing an additional 110,000 shares during the quarter. Farallon Capital Management LLC owned about 0.10% of Beta Bionics worth $85,718,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. GPS Wealth Strategies Group LLC boosted its holdings in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares during the period. Strs Ohio purchased a new position in Beta Bionics in the 1st quarter worth approximately $29,000. EverSource Wealth Advisors LLC increased its stake in Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares during the period. Legal & General Group Plc lifted its position in Beta Bionics by 197.4% in the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after purchasing an additional 2,639 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in Beta Bionics by 139.1% in the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after purchasing an additional 1,863 shares during the last quarter.

Insiders Place Their Bets

In other Beta Bionics news, insider Mike Mensinger sold 7,800 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.61, for a total transaction of $230,958.00. Following the transaction, the insider directly owned 82,952 shares of the company’s stock, valued at approximately $2,456,208.72. The trade was a 8.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This trade represents a 31.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 34,705 shares of company stock worth $945,653.

Analyst Ratings Changes

BBNX has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. TD Cowen began coverage on shares of Beta Bionics in a report on Monday, January 26th. They set a “hold” rating and a $17.00 price target for the company. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Stifel Nicolaus cut their price target on shares of Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Finally, Lake Street Capital set a $20.00 price objective on shares of Beta Bionics in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $10.39 on Monday. The firm has a market cap of $461.11 million, a P/E ratio of -5.33 and a beta of 5.59. Beta Bionics, Inc. has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The business’s 50 day moving average price is $15.52 and its 200-day moving average price is $22.07.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Tuesday, February 17th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. The company had revenue of $32.12 million during the quarter. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.